Bessemer Group Inc. Sells 12,800 Shares of Myokardia Inc (MYOK)
Bessemer Group Inc. reduced its stake in Myokardia Inc (NASDAQ:MYOK) by 53.2% during the 4th quarter, Holdings Channel reports. The firm owned 11,278 shares of the biotechnology company’s stock after selling 12,800 shares during the period. Bessemer Group Inc.’s holdings in Myokardia were worth $475,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of MYOK. Wells Fargo & Company MN lifted its holdings in Myokardia by 2,151.7% during the third quarter. Wells Fargo & Company MN now owns 417,439 shares of the biotechnology company’s stock worth $17,887,000 after acquiring an additional 398,900 shares in the last quarter. VHCP Management II LLC bought a new position in Myokardia during the third quarter worth about $11,355,000. RTW Investments LP bought a new position in Myokardia during the third quarter worth about $10,882,000. Fernwood Investment Management LLC lifted its holdings in Myokardia by 409.1% during the third quarter. Fernwood Investment Management LLC now owns 246,382 shares of the biotechnology company’s stock worth $10,557,000 after acquiring an additional 197,989 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. bought a new position in Myokardia during the third quarter worth about $4,542,000. Institutional investors and hedge funds own 63.75% of the company’s stock.
Shares of Myokardia Inc (MYOK) opened at $49.65 on Tuesday. The company has a market capitalization of $1,770.00 and a PE ratio of -67.09. Myokardia Inc has a twelve month low of $10.80 and a twelve month high of $55.40.
In other news, insider Joseph Lambing sold 5,000 shares of the business’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $50.00, for a total value of $250,000.00. Following the sale, the insider now directly owns 95,846 shares in the company, valued at $4,792,300. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Anastasios Gianakakos sold 3,000 shares of the business’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $41.09, for a total value of $123,270.00. Following the completion of the sale, the insider now owns 512,117 shares in the company, valued at $21,042,887.53. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 840,326 shares of company stock worth $35,376,662. Corporate insiders own 33.40% of the company’s stock.
Myokardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Want to see what other hedge funds are holding MYOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myokardia Inc (NASDAQ:MYOK).
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.